Loncom Pharmaceutical's Revefenacin API is a novel therapeutic agent for managing chronic obstructive pulmonary disease (COPD). As a long-acting muscarinic antagonist, it is designed for daily maintenance treatment of COPD, underscoring our dedication to advancing respiratory care.
Shandong Loncom Pharmaceutical Co., Ltd is founded in 2012, located in Qihe Economic Development Zone, Shandong Province, with a registered capital of 60 million yuan.
